Edition:
United States

Eiger BioPharmaceuticals Inc (EIGR.OQ)

EIGR.OQ on NASDAQ Stock Exchange Global Market

11.75USD
4:00pm EDT
Change (% chg)

$-0.10 (-0.84%)
Prev Close
$11.85
Open
$11.95
Day's High
$11.95
Day's Low
$11.60
Volume
15,079
Avg. Vol
38,799
52-wk High
$18.00
52-wk Low
$7.50

Chart for

About

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe... (more)

Overall

Beta: 1.64
Market Cap(Mil.): $162.77
Shares Outstanding(Mil.): 13.74
Dividend: --
Yield (%): --

Financials

  EIGR.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -3.87 -- --
ROI: -76.04 2.89 12.63
ROE: -110.96 1.65 14.82

BRIEF-Eiger Biopharmaceuticals Announces Proposed Public Offering Of Common Stock

* EIGER BIOPHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

May 23 2018

BRIEF-Progeria Research Foundation Announces Collaboration, Supply Agreement With Eiger Biopharma

* PROGERIA RESEARCH FOUNDATION ANNOUNCES COLLABORATION AND SUPPLY AGREEMENT WITH EIGER BIOPHARMACEUTICALS Source text for Eikon: Further company coverage:

May 16 2018

BRIEF-Eiger Announces Expanded License Agreement With Merck For Lonafarnib

* EIGER ANNOUNCES EXPANDED LICENSE AGREEMENT WITH MERCK FOR INVESTIGATIONAL CANDIDATE LONAFARNIB AND COLLABORATION WITH THE PROGERIA RESEARCH FOUNDATION (PRF) Source text for Eikon: Further company coverage:

May 16 2018

BRIEF-Eiger Biopharmaceuticals Reports First Quarter 2018 Financial Results

* EIGER BIOPHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 11 2018

BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018​

* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM

Mar 21 2018

BRIEF-Eiger Biopharmaceuticals Q4 Loss Per Share $1.11

* EIGER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 12 2018

Earnings vs. Estimates